肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2022 MASCC专家意见：临床辅助营养在晚期癌症患者中的应用

2022-04-01 癌症支持疗法多国学会 Support Care Cancer

晚期癌症临床辅助营养

2022年4月，癌症支持疗法多国学会(MASCC)发布了临床辅助营养在晚期癌症患者中的应用专家指导意见。临床辅助营养在重症癌症患者中的应用前景存在争议，缺乏具体的指导。本文主要针对临床辅助营养在晚期癌

中文标题：

2022 MASCC专家意见：临床辅助营养在晚期癌症患者中的应用

英文标题：

Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/guidance on the use of clinically assisted nutrition in patients with advanced cancer

发布机构：

癌症支持疗法多国学会

发布日期：

2022-04-01

简要介绍：

2022年4月，癌症支持疗法多国学会(MASCC)发布了临床辅助营养在晚期癌症患者中的应用专家指导意见。临床辅助营养在重症癌症患者中的应用前景存在争议，缺乏具体的指导。本文主要针对临床辅助营养在晚期癌症患者中的应用提供指导意见。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 MASCC专家意见：临床辅助营养在晚期癌症患者中的应用.pdf)] GetToolGuiderByIdResponse(projectId=1, id=fde491c002a06ee5, title=2022 MASCC专家意见：临床辅助营养在晚期癌症患者中的应用, enTitle=Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/guidance on the use of clinically assisted nutrition in patients with advanced cancer, guiderFrom=Support Care Cancer, authorId=0, author=, summary=2022年4月，癌症支持疗法多国学会(MASCC)发布了临床辅助营养在晚期癌症患者中的应用专家指导意见。临床辅助营养在重症癌症患者中的应用前景存在争议，缺乏具体的指导。本文主要针对临床辅助营养在晚期癌, cover=https://img.medsci.cn/20220408/1649424916413_1608702.jpg, journalId=0, articlesId=null, associationId=993, associationName=癌症支持疗法多国学会, associationIntro=MASCC是癌症支持疗法多国学会的缩写，是一涉及癌症支持疗法的多学科的国际性组织。成员来自各大洲的60多个国家。MASCC成立于1990年，该组织致力于对各期癌症病人支持疗法各个方面的研究及教育。MASCC的工作目标是通过研究及科学认识的交流，提高支持疗法的专业水平。, copyright=0, guiderPublishedTime=Fri Apr 01 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2022年4月，癌症支持疗法多国学会(MASCC)发布了临床辅助营养在晚期癌症患者中的应用专家指导意见。临床辅助营养在重症癌症患者中的应用前景存在争议，缺乏具体的指导。本文主要针对临床辅助营养在晚期癌症患者中的应用提供指导意见。</span></p>, tagList=[TagDto(tagId=3325, tagName=晚期癌症), TagDto(tagId=436432, tagName=临床辅助营养)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2908, appHits=129, showAppHits=0, pcHits=275, showPcHits=2779, likes=1, shares=36, comments=9, approvalStatus=1, publishedTime=Sat Apr 09 15:33:00 CST 2022, publishedTimeString=2022-04-01, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Fri Apr 08 21:37:07 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Fri Jan 05 13:04:47 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 MASCC专家意见：临床辅助营养在晚期癌症患者中的应用.pdf)])
2022 MASCC专家意见：临床辅助营养在晚期癌症患者中的应用.pdf
下载请点击：
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2129797, encodeId=a8062129e970b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f076405107, createdName=ms2000001680053118, createdTime=Wed May 03 02:47:47 CST 2023, time=2023-05-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2120013, encodeId=5ef2212001398, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f076405107, createdName=ms2000001680053118, createdTime=Thu Mar 16 20:01:15 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1210672, encodeId=300a12106e2ff, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4aa2550256, createdName=铜鼎元帅, createdTime=Tue Apr 12 21:22:52 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210671, encodeId=d40f12106e1d0, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4aa2550256, createdName=铜鼎元帅, createdTime=Tue Apr 12 21:22:20 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210448, encodeId=00fd121044847, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue Apr 12 07:34:59 CST 2022, time=2022-04-12, status=1, ipAttribution=)]
    2023-05-03 ms2000001680053118 来自广西

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2129797, encodeId=a8062129e970b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f076405107, createdName=ms2000001680053118, createdTime=Wed May 03 02:47:47 CST 2023, time=2023-05-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2120013, encodeId=5ef2212001398, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f076405107, createdName=ms2000001680053118, createdTime=Thu Mar 16 20:01:15 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1210672, encodeId=300a12106e2ff, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4aa2550256, createdName=铜鼎元帅, createdTime=Tue Apr 12 21:22:52 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210671, encodeId=d40f12106e1d0, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4aa2550256, createdName=铜鼎元帅, createdTime=Tue Apr 12 21:22:20 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210448, encodeId=00fd121044847, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue Apr 12 07:34:59 CST 2022, time=2022-04-12, status=1, ipAttribution=)]
    2023-03-16 ms2000001680053118 来自广西

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2129797, encodeId=a8062129e970b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f076405107, createdName=ms2000001680053118, createdTime=Wed May 03 02:47:47 CST 2023, time=2023-05-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2120013, encodeId=5ef2212001398, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f076405107, createdName=ms2000001680053118, createdTime=Thu Mar 16 20:01:15 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1210672, encodeId=300a12106e2ff, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4aa2550256, createdName=铜鼎元帅, createdTime=Tue Apr 12 21:22:52 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210671, encodeId=d40f12106e1d0, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4aa2550256, createdName=铜鼎元帅, createdTime=Tue Apr 12 21:22:20 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210448, encodeId=00fd121044847, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue Apr 12 07:34:59 CST 2022, time=2022-04-12, status=1, ipAttribution=)]
    2022-04-12 铜鼎元帅

    #肿瘤#非常实用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2129797, encodeId=a8062129e970b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f076405107, createdName=ms2000001680053118, createdTime=Wed May 03 02:47:47 CST 2023, time=2023-05-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2120013, encodeId=5ef2212001398, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f076405107, createdName=ms2000001680053118, createdTime=Thu Mar 16 20:01:15 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1210672, encodeId=300a12106e2ff, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4aa2550256, createdName=铜鼎元帅, createdTime=Tue Apr 12 21:22:52 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210671, encodeId=d40f12106e1d0, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4aa2550256, createdName=铜鼎元帅, createdTime=Tue Apr 12 21:22:20 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210448, encodeId=00fd121044847, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue Apr 12 07:34:59 CST 2022, time=2022-04-12, status=1, ipAttribution=)]
    2022-04-12 铜鼎元帅

    非常实用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2129797, encodeId=a8062129e970b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f076405107, createdName=ms2000001680053118, createdTime=Wed May 03 02:47:47 CST 2023, time=2023-05-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2120013, encodeId=5ef2212001398, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f076405107, createdName=ms2000001680053118, createdTime=Thu Mar 16 20:01:15 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1210672, encodeId=300a12106e2ff, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4aa2550256, createdName=铜鼎元帅, createdTime=Tue Apr 12 21:22:52 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210671, encodeId=d40f12106e1d0, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4aa2550256, createdName=铜鼎元帅, createdTime=Tue Apr 12 21:22:20 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210448, encodeId=00fd121044847, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue Apr 12 07:34:59 CST 2022, time=2022-04-12, status=1, ipAttribution=)]
    2022-04-12 1064510_1039

    #肿瘤#

    0

相关指南

2021 MASCC指南：晚期癌症患者恶性肠梗阻的内科管理（更新版）

癌症支持疗法多国学会(MASCC,Multinational Association of Supportive Care in Cancer) · 2021-08-14

2016 JSPM指南：晚期癌症患者肠外液体管理

日本姑息医学会(JSPM,Japanese Society of Palliative Medicine) · 2016-08-12